Try our beta test site
10 studies found for:    Selinexor | lymphoma OR CLL | Selinexor
Show Display Options
Rank Status Study
1 Recruiting Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Selinexor
2 Recruiting A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Condition: B-cell Lymphoma
Interventions: Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine
3 Terminated Efficacy & Safety Study of Selinexor in Relapsed/Refractory Peripheral T-cell Lymphoma & Cutaneous T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (PTCL);   Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Selinexor
4 Suspended Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Conditions: Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Selinexor;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
5 Recruiting KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: KPT-330;   Drug: Rituximab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Dexamethasone
6 Active, not recruiting Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Conditions: Childhood Central Nervous System Neoplasm;   Childhood Lymphoma;   Childhood Solid Neoplasm;   Malignant Glioma;   Recurrent Brain Neoplasm
Interventions: Other: Pharmacological Study;   Drug: Selinexor
7 Active, not recruiting Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Condition: Hematological Malignancies
Intervention: Drug: KPT-330
8 Terminated Selinexor in Initial or Relapsed/Refractory Richter's Transformation
Condition: Richter's Transformation
Intervention: Drug: selinexor
9 Active, not recruiting Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Conditions: Relapsed Acute Lymphoblastic Leukemia (ALL);   Refractory Acute Lymphoblastic Leukemia (ALL);   Relapsed Acute Myelogenous Leukemia (AML);   Refractory Acute Myelogenous Leukemia (AML);   Relapsed Mixed Lineage Leukemia;   Refractory Mixed Lineage Leukemia;   Relapsed Biphenotypic Leukemia;   Refractory Biphenotypic Leukemia;   Chronic Myelogenous Leukemia (CML) in Blast Crisis
Intervention: Drug: KPT-330
10 Completed Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Drug: Selinexor;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: methotrexate/hydrocortisone/cytarabine

Study has passed its completion date and status has not been verified in more than two years.